Mesoglicano endovescicale nel trattamento della "painful bladder syndrome" femminile

OBJECTIVES: The aim of our study was to test the effect of Mesoglican in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients.METHODS: A total of 42 female patients completed the study. Patients received endovesical administration of Mesoglican in normal saline, 50 ml, weekly for 12 weeks. We administered VAS questionnaire to evaluate the improvement in bladder pain and QoL. Frequency, urgency and nocturia were analized by using the voiding diaries.RESULTS: After 12 weeks treatment, pelvic pain, urgency and nocturia showed a mean significant improvement. VAS pain score decreased from 5,8 to 3,6. The mean voiding volumes revealed significant increase after the 12 weeks' treatment period. Mean voiding volume increased from 138 ml to 196, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15 to 12,5). The average number of episodes of urgency decreased from 9,0 to 6,0 and nocturia from 4,0 to 2,0 after the treatment cycle, showing a significant improvement. The average QoL VAS score increased from 2,8 to 6,4.CONCLUSIONS: In our preliminary experience, the administration of intravesical Mesoglican appears to be a safe and efficacious method of treatment in IC/PBS.